| Authors: |
M M; Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER)-Kolkata, West Bengal, India., S M; Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER)-Kolkata, West Bengal, India., Kate SS; Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER)-Kolkata, West Bengal, India., Taneja I; Translational PK/PD and Investigative Toxicology, Johnson & Johnson Innovative Medicine, Spring House, Pennsylvania., Jaiswal S; Certara Predictive Technologies, Simcyp Division, Certara Inc, Radnor, Pennsylvania., Pratap B; Research and Development, Rosemont Pharmaceuticals, Leeds, United Kingdom., Rathi PC; Augmented DMTA Platform, R&D IT, AstraZeneca, The Discovery Centre (DISC), Cambridge, United Kingdom., Thakur S; School of Medical Science and Technology, Indian Institute of Technology (IIT) Kharagpur, Kharagpur, West Bengal, India., Paul D; Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER)-Kolkata, West Bengal, India. Electronic address: davidpaul@niperkolkata.ac.in., Wahajuddin M; Institute of Cancer Therapeutics, School of Pharmacy and Medical Sciences, Faculty of Life Sciences, University of Bradford, Bradford, United Kingdom. Electronic address: m.wahajuddin@bradford.ac.uk. |